STOCK TITAN

BVF funds sell 1.63M Kymera Therapeutics (KYMR) shares at $106.50

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Kymera Therapeutics’ large shareholder group BVF and related entities reported a significant secondary-market sale and updated their ownership. On June 26, 2026, BVF-affiliated funds and a managed account sold an aggregate 1,630,658 Kymera shares at $106.50 per share.

After these trades, BVF, BVF2, Biotechnology Value Trading Fund OS and the Partners Managed Account together beneficially own 5,237,151 shares, or approximately 6.3% of Kymera’s common stock, based on 82,257,588 shares outstanding as of April 24, 2026 plus shares underlying certain pre-funded warrants.

The group holds 1,365,099 pre-funded warrants with a de minimis $0.0001 exercise price that do not expire, subject to a 9.99% ownership cap and Hart-Scott-Rodino thresholds. Director Gorjan Hrustanovic’s board-related stock options, covering 116,190 shares vesting within 60 days, are subject to an agreement assigning their economic benefit to BVF Partners.

Positive

  • None.

Negative

  • None.

Insights

BVF trimmed its Kymera position but remains a 6.3% holder.

BVF and related entities disclosed selling 1,630,658 Kymera shares at $106.50 per share. Despite this reduction, they still beneficially own 5,237,151 shares, or about 6.3% of the company, keeping them an important institutional shareholder.

The filing details 1,365,099 pre-funded warrants with a nominal $0.0001 exercise price and no expiry, constrained by a 9.99% ownership blocker and Hart-Scott-Rodino thresholds. These mechanics limit how quickly BVF can increase its stake via warrant exercise.

Director Gorjan Hrustanovic holds stock options over 116,190 shares that have vested or will vest within 60 days, with their economic benefit assigned to BVF Partners under a separate agreement. Subsequent ownership disclosures will show how BVF balances future warrant exercises, open-market activity and board-related equity awards.

Shares outstanding 82,257,588 shares Common shares outstanding as of April 24, 2026
Aggregate BVF group holding 5,237,151 shares Beneficially owned, representing about 6.3% of common stock
June 26, 2026 sale volume 1,630,658 shares Shares sold by BVF entities and managed account at $106.50
Sale price $106.50 per share Price for the June 26, 2026 aggregate sale
Pre-funded warrants held 1,365,099 warrants Exercisable into same number of shares at $0.0001
Warrant exercise price $0.0001 per share Exercise price for Kymera pre-funded warrants
BVF ownership percentage 6.3% Group beneficial ownership of Kymera common stock
Hrustanovic options 116,190 shares Shares underlying vested or near-term vesting stock options
Pre-Funded Warrants financial
"The aggregate purchase price of the 751,971 pre-funded warrants (the "Pre-Funded Warrants") owned by BVF is approximately..."
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Warrants Blocker regulatory
"A holder of Pre-Funded Warrants will not be entitled to exercise... exceed 9.99%... (the "Warrants Blocker")."
Hart-Scott-Rodino Act regulatory
"the notification threshold (the "HSR Threshold") applicable to the holder under the Hart-Scott-Rodino Act (the "HSR Act")..."
A U.S. antitrust law that requires parties to large mergers and acquisitions to notify federal regulators and wait a set period before closing the deal, so authorities can check whether the transaction would unfairly reduce competition. For investors, the process is like notifying a referee before a major team trade: it can reveal objections, trigger investigations, delay or block a deal, and therefore affect transaction timing, value and deal risk.
HSR Threshold regulatory
"if the exercise of a Pre-Funded Warrant would result... equal to or in excess of the notification threshold (the "HSR Threshold")..."
beneficially owned financial
"As of the date hereof, (i) BVF beneficially owned 2,712,852 Shares, including 751,971 Shares underlying the Pre-Funded Warrants..."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
working capital financial
"were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms...)"
Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What Kymera Therapeutics (KYMR) share sale did BVF report in this Schedule 13D/A?

BVF and related entities reported selling an aggregate 1,630,658 Kymera shares at a price of $106.50 per share on June 26, 2026. Individual sales came from BVF, BVF2, Biotechnology Value Trading Fund OS and the Partners Managed Account.

What pre-funded warrants on Kymera Therapeutics (KYMR) shares does BVF hold?

BVF and related accounts hold 1,365,099 pre-funded warrants exercisable into the same number of Kymera shares at an exercise price of $0.0001 per share. These warrants do not expire but are limited by a 9.99% ownership blocker and Hart-Scott-Rodino thresholds.

How is BVF’s percentage ownership in Kymera Therapeutics (KYMR) calculated?

BVF’s group ownership of approximately 6.3% is calculated using 82,257,588 Kymera shares outstanding as of April 24, 2026, plus certain or all of the 1,365,099 shares underlying the pre-funded warrants held by BVF entities and the Partners Managed Account, as described in the filing.

What Kymera Therapeutics (KYMR) stock options does director Gorjan Hrustanovic hold?

Director Gorjan Hrustanovic beneficially owns 116,190 Kymera shares underlying stock options that have vested or will vest within 60 days. An additional 6,068 option shares have not yet vested. He has agreed to transfer any economic benefit from exercising these options to BVF Partners.

What is the Warrants Blocker mentioned for Kymera Therapeutics (KYMR) pre-funded warrants?

The Warrants Blocker prevents any holder from exercising pre-funded warrants if doing so would push their beneficial ownership above 9.99% of Kymera’s outstanding shares. As of the filing date, this blocker does not restrict BVF’s ability to exercise its pre-funded warrants.





501575104

(CUSIP Number)
JAMES KRATKY
BVF PARTNERS L.P., 44 Montgomery St., 40th Floor
San Francisco, CA, 94104
415-525-8830

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
06/26/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:06/26/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:06/26/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:06/26/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:06/26/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:06/26/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:06/26/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:06/26/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:06/26/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:06/26/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:06/26/2026
Hrustanovic Gorjan
Signature:/s/ Gorjan Hrustanovic
Name/Title:Gorjan Hrustanovic
Date:06/26/2026